The $280m project increases the site’s workforce by around 200 and adds two new buildings to the 89-acre campus. The expansion project brings the company’s total investment in the site to more than $1bn.
The new facilities add approximately 200,000 square feet in space, and will include a Biologics Development Building for designing processes for investigational medicines’ early production, and a Clinical Manufacturing Building where the medicines will be produced to support clinical trials.
“This project represents a significant expansion in the site’s size and mission,” said Greg Guyer, senior vice president, Biologics Development and Operations.
According to the company, both are new capabilities for the campus, which previously focused on large-scale, bulk biologics manufacturing.
“Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president, Global Manufacturing & Supply. “Bringing together biologics development and clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide.”